These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 35538909)

  • 1. Chemoradiation followed by adjuvant durvalumab in stage III non-small cell lung cancer: Real-world comparison of treatment outcomes to historical controls treated with chemoradiation alone.
    Saad A; Goldstein J; Appel S; Daher S; Urban D; Onn A; Gantz-Sorotsky H; Lobachov A; Gottfried T; Spieler B; Bar J
    Thorac Cancer; 2022 Jun; 13(12):1763-1771. PubMed ID: 35538909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
    Desilets A; Blanc-Durand F; Lau S; Hakozaki T; Kitadai R; Malo J; Belkaid W; Richard C; Messaoudene M; Cvetkovic L; Kazandjian S; Tehfe M; Florescu M; Jao K; Daaboul N; Owen S; Shieh B; Agulnik J; Cohen V; Charbonneau C; Marcoux N; Blais N; Leighl NB; Bradbury PA; Liu G; Shepherd FA; Bahig H; Routy B; Sacher A; Elkrief A
    Eur J Cancer; 2021 Jan; 142():83-91. PubMed ID: 33242835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.
    Nindra U; Shahnam A; Stevens S; Pal A; Nagrial A; Lee J; Yip PY; Adam T; Boyer M; Kao S; Bray V
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):16-24. PubMed ID: 36855021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.
    Bryant AK; Sankar K; Strohbehn GW; Zhao L; Daniel V; Elliott D; Ramnath N; Green MD
    Int J Radiat Oncol Biol Phys; 2022 Jul; 113(4):752-758. PubMed ID: 35450753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.
    Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
    Park JE; Hong KS; Choi SH; Lee SY; Shin KC; Jang JG; Kwon YS; Park SH; Choi KJ; Jung CY; Eom JS; Kim S; Seol HY; Kim J; Kim I; Park JH; Kim TH; Ahn JH
    Clin Lung Cancer; 2024 Jun; 25(4):354-364. PubMed ID: 38503590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.
    Durm GA; Jabbour SK; Althouse SK; Liu Z; Sadiq AA; Zon RT; Jalal SI; Kloecker GH; Williamson MJ; Reckamp KL; Langdon RM; Kio EA; Gentzler RD; Adesunloye BA; Harb WA; Walling RV; Titzer ML; Hanna NH
    Cancer; 2020 Oct; 126(19):4353-4361. PubMed ID: 32697352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.
    Bryant AK; Sankar K; Strohbehn GW; Zhao L; Elliott D; Daniel V; Ramnath N; Green MD
    Int J Radiat Oncol Biol Phys; 2022 May; 113(1):60-65. PubMed ID: 35115216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
    Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer.
    Bryant AK; Sankar K; Zhao L; Strohbehn GW; Elliott D; Moghanaki D; Kelley MJ; Ramnath N; Green MD
    Eur J Cancer; 2022 Aug; 171():55-63. PubMed ID: 35704975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
    Gómez Rueda A; Taus Á; Álvarez Álvarez R; Bernabé-Caro R; Chara L; López-Brea M; Vilà L; Sala González MÁ; Del Barrio Díaz Aldagalán A; Esteban Herrera B; López Castro R; Álvarez Cabellos R; Doménech M; Falagan S; Moreno Vega A; Aguado C; Barba A; Delgado Ureña MT; Isla D; Bellido Hernández L; Fírvida Pérez JL; Juan-Vidal Ó; Massutí B; Mielgo-Rubio X; Ortega AL; Catot S; Dómine M; Escoín-Pérez C; García Navalón F; Gil-Bazo I; Muñoz S; Rodríguez-Abreu D; Villatoro Roldán RM; Alonso-Jáudenes Curbera G; León-Mateos L; Padilla A; Paredes Lario A; Sánchez-Torres JM; Garrido P;
    Clin Transl Oncol; 2024 Jul; 26(7):1779-1789. PubMed ID: 38512450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
    Offin M; Shaverdian N; Rimner A; Lobaugh S; Shepherd AF; Simone CB; Gelblum DY; Wu AJ; Lee N; Kris MG; Rudin CM; Zhang Z; Hellmann MD; Chaft JE; Gomez DR
    Radiother Oncol; 2020 Aug; 149():205-211. PubMed ID: 32361014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study.
    Trinh JQ; Xiong Y; Smith LM; Abughanimeh O; Marr AS; Ganti AK
    Anticancer Res; 2024 Feb; 44(2):605-612. PubMed ID: 38307589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for Stage III Nonsmall-cell Lung Cancer.
    Bryant AK; Yin H; Schipper MJ; Paximadis PA; Boike TP; Bergsma DP; Movsas B; Dess RT; Mietzel MA; Kendrick R; Seferi M; Dominello MM; Matuszak MM; Jagsi R; Hayman JA; Pierce LJ; Jolly S;
    Am J Clin Oncol; 2022 Apr; 45(4):142-145. PubMed ID: 35271524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179.
    Anouti B; Althouse S; Durm G; Hanna N
    Clin Lung Cancer; 2020 May; 21(3):288-293. PubMed ID: 32143966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
    Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA
    Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
    Bruni A; Scotti V; Borghetti P; Vagge S; Cozzi S; D'Angelo E; Giaj Levra N; Fozza A; Taraborrelli M; Piperno G; Vanoni V; Sepulcri M; Trovò M; Nardone V; Lattanzi E; Bou Selman S; Bertolini F; Franceschini D; Agustoni F; Jereczek-Fossa BA; Magrini SM; Livi L; Lohr F; Filippi AR
    Front Oncol; 2021; 11():744956. PubMed ID: 34650927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non-small cell lung cancer.
    McCall NS; Janopaul-Naylor JR; McGinnis HS; Kesarwala AH; Tian S; Stokes WA; Shelton JW; Steuer CE; Carlisle JW; Leal TA; Ramalingam SS; Bradley JD; Higgins KA
    Cancer; 2023 Dec; 129(23):3713-3723. PubMed ID: 37354070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of Enhanced Locoregional Control to Improved Overall Survival with Consolidative Durvalumab after Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer: Insights from Real-World Data.
    Jang JY; Song SY; Shin YS; Kim HU; Choi EK; Kim SW; Lee JC; Lee DH; Choi CM; Yoon S; Kim SS
    Cancer Res Treat; 2024 Jul; 56(3):785-794. PubMed ID: 38228082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer.
    Preti BTB; Sanatani MS; Breadner D; Lakkunarajah S; Scott C; Esmonde-White C; McArthur E; Rodrigues G; Chaudhary M; Mutsaers A; Sachdeva R; Vincent MD
    Curr Oncol; 2023 Aug; 30(8):7713-7721. PubMed ID: 37623040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.